13.10.2024, 862 Zeichen

Marinomed: Marinomed Biotech AG has published clinical data from the phase II dose-finding clinical trial evaluating the efficacy of Tacrosolv eye drops in patients with allergic rhinoconjunctivitis in the peer-reviewed “Clinical Ophthalmology” journal. The placebo-controlled allergen challenge trial assessed the efficacy and safety of two different doses of Tacrosolv. The results show that the higher dose of Tacrosolv eye drops (0.005% Tacrolimus) significantly reduced ocular symptoms of allergic conjunctivitis, and surprisingly, also the associated nasal allergy symptoms. Remarkably, these results were achieved with a dose that is 20-fold lower than that of the only Tacrolimus eye drop product currently on the market.
Marinomed Biotech: weekly performance: 0.21%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (08/10/2024)

Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #1133: ATX schwächer, Auftakt zur Zürs-Konferenz und damit zur Main Event Woche mit etwas Neuem auch von uns

Bildnachweis

Aktien auf dem Radar:Rosenbauer, RBI, Österreichische Post, Semperit, Austriacard Holdings AG, EuroTeleSites AG, Amag, VIG, Uniqa, Bajaj Mobility AG, FACC, Rosgix, CPI Europe AG, Marinomed Biotech, SW Umwelttechnik, Addiko Bank, BKS Bank Stamm, Athos Immobilien, BTV AG, Oberbank AG Stamm, DO&CO, CA Immo, Telekom Austria.

---